16,797 Shares in Moderna, Inc. $MRNA Purchased by Cibc World Market Inc.

Key Points

• CIBC World Markets purchased 16,797 Moderna shares worth approximately $1.18 million in the second quarter, while institutional investors overall own 75.33% of the company.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and average price target of $74.31, despite several analysts raising targets as high as $135.
• Moderna’s outlook includes FDA approval for updated COVID-19 vaccines and promising personalized cancer-vaccine results, but the company remains unprofitable and plans to raise up to $2.3 billion through convertible notes, creating potential dilution concerns.

Cibc World Market Inc. purchased a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 16,797 shares of the company's stock, valued at approximately $1,176,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. MUFG Securities EMEA plc acquired a new stake in shares of Moderna in the second quarter worth approximately $28,000. Allied Private Wealth LLC acquired a new position in Moderna during the second quarter worth approximately $30,000. Canton Hathaway LLC acquired a new position in Moderna during the first quarter worth approximately $31,000. EverSource Wealth Advisors LLC raised its stake in Moderna by 148.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company's stock worth $37,000 after purchasing an additional 801 shares during the period. Finally, Assetmark Inc. raised its stake in Moderna by 35.1% during the first quarter. Assetmark Inc. now owns 801 shares of the company's stock worth $41,000 after purchasing an additional 208 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several research reports. Barclays boosted their price objective on shares of Moderna from $48.00 to $125.00 and gave the company an "equal weight" rating in a research note on Monday. Loop Capital set a $135.00 price objective on Moderna in a research note on Wednesday, August 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Moderna in a report on Friday, June 12th. William Blair raised shares of Moderna from a "market perform" rating to an "outperform" rating in a research report on Wednesday, August 19th. Finally, Royal Bank Of Canada reissued a "sector perform" rating and set a $130.00 target price on shares of Moderna in a research report on Wednesday, August 19th. Four investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Moderna has a consensus rating of "Hold" and an average target price of $74.31.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: The FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, which target the XFG subvariant. The approval supports Moderna’s ability to participate in the upcoming seasonal vaccination market, although Spikevax eligibility is focused on adults 65 and older and higher-risk people ages 6 months through 64. FDA approves updated COVID vaccines
• Positive Sentiment: Renewed attention on Moderna and Merck’s personalized cancer vaccine, intismeran, is supporting the company’s long-term oncology story. Reports indicate the therapy reduced melanoma recurrence by approximately 49% in a late-stage study, strengthening expectations that Moderna could diversify beyond its declining COVID-19 business. Personalized melanoma vaccine results
• Neutral Sentiment: Moderna announced plans to raise $2 billion through convertible senior notes due in 2032, with an option for purchasers to increase the deal to $2.3 billion. Proceeds may fund oncology investments and debt repayment, while a hedge overlay is intended to offset dilution up to a specified cap. Moderna convertible notes offering
• Negative Sentiment: Investors are reacting cautiously to the financing because convertible notes can create future share dilution and signal substantial funding needs. The offering comes while Moderna remains unprofitable, making the company’s elevated valuation more difficult to justify on current earnings and revenue. Moderna borrows $2 billion

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 3,471 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the sale, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the firm's stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the sale, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.80% of the stock is currently owned by company insiders.

Moderna Stock Down 4.6%

Shares of Moderna stock opened at $142.77 on Friday. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $176.66. The stock has a market cap of $57.00 billion, a price-to-earnings ratio of -17.87 and a beta of 0.91. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average price of $75.62 and a 200 day moving average price of $59.17.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. The company had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm's revenue was up 2.1% compared to the same quarter last year. During the same period last year, the company posted ($2.13) earnings per share. Equities research analysts forecast that Moderna, Inc. will post -6.18 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source